Tak Paul Peter, CEO of Candel Therapeutics ($CADL), sold shares on the open market twice in the last year, totaling about $230,000. His most recent sale occurred on March 19, 2025. These sales rank 8,126th among over 11,600 insiders, compared to an average sale value of $8.6 million across about six transactions per insider. He made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 26, 2026 | Candel Therapeutics, Inc. | $CADL | Tak Paul Peter | Chief Executive Officer | A | Stock Option (Right to Buy) | 629000 | $0.00 | 629,000.0000 | 55,018,457 | 9999.99% | 1.14% |
| June 25, 2025 | Candel Therapeutics, Inc. | $CADL | Tak Paul Peter | Chief Executive Officer | A | Common Stock | 42826 | $4.67 | 268,566.0000 | 46,933,088 | 18.97% | 0.09% |
| March 19, 2025 | Candel Therapeutics, Inc. | $CADL | Tak Paul Peter | Chief Executive Officer | S | Common Stock | 400 | $9.00 | 225,740.0000 | 46,933,088 | 0.18% | 0.00% |
| March 18, 2025 | Candel Therapeutics, Inc. | $CADL | Tak Paul Peter | Chief Executive Officer | S | Common Stock | 25772 | $8.77 | 226,140.0000 | 46,933,088 | 10.23% | 0.05% |
| Feb. 12, 2025 | Candel Therapeutics, Inc. | $CADL | Tak Paul Peter | Chief Executive Officer | A | Stock Option (Right to Buy) | 525000 | $0.00 | 525,000.0000 | 46,933,088 | 9999.99% | 1.12% |
| Jan. 15, 2025 | Candel Therapeutics, Inc. | $CADL | Tak Paul Peter | Chief Executive Officer | S | Common Stock | 21704 | $7.23 | 251,912.0000 | 46,933,088 | 7.93% | 0.05% |
| Jan. 8, 2025 | Candel Therapeutics, Inc. | $CADL | Tak Paul Peter | Chief Executive Officer | S | Common Stock | 21172 | $8.22 | 273,616.0000 | 46,933,088 | 7.18% | 0.05% |
| Nov. 29, 2024 | Candel Therapeutics, Inc. | $CADL | Tak Paul Peter | Chief Executive Officer | S | Common Stock | 48847 | $4.56 | 294,788.0000 | 32,247,744 | 14.21% | 0.15% |
| Nov. 21, 2024 | Candel Therapeutics, Inc. | $CADL | Tak Paul Peter | Chief Executive Officer | M | Common Stock | 12900 | $1.55 | 343,635.0000 | 32,247,744 | 3.90% | 0.04% |
| Nov. 21, 2024 | Candel Therapeutics, Inc. | $CADL | Tak Paul Peter | Chief Executive Officer | M | Stock Option (Right to Buy) | 12900 | $0.00 | 1,763,968.0000 | 32,247,744 | 0.73% | 0.04% |
| July 17, 2024 | Candel Therapeutics, Inc. | $CADL | Tak Paul Peter | Chief Executive Officer | S | Common Stock | 22528 | $6.47 | 330,735.0000 | 31,186,817 | 6.38% | 0.07% |
| July 11, 2024 | Candel Therapeutics, Inc. | $CADL | Tak Paul Peter | Chief Executive Officer | S | Common Stock | 20293 | $5.97 | 353,263.0000 | 31,186,817 | 5.43% | 0.07% |